mesenchyme

Atrium NatCell Mesenchyme at Fubao Health

Atrium NatCell Mesenchyme

http://www.fubaohealth.com/mesenchyme.html

FROZEN PRODUCT

NatCell Mesenchyme provides a high concentration
neurotrophic and other growth factors necessary for normal nervous system function, muscular contractions, nerve impulses and endocrine functions, and may helps promote cellular metabolic activity.

Our Naturopath has used the NatCell line of glandular Extracts countless times with excellent results with many clients suffering from chronic fatigue, frank adrenal exhaustion, other degenerative, stress related conditions, and more.

Directions: Thaw bottle by holding in hand. Open bottle and drink the entire contents. Take on an empty stomach in the morning or evening either a half hour before or two hours after a meal.

Ingredients: Serving Size: 1 BottleServings Per Package: 8Each Bottle Contains: Porcine Mesenchyme Aqueous Extract 125X…….. 0. 3 oz (9 ml0
We will have this product shipped to you direct from the manufacturer by FedEx Next Day Air.
NO RETURN OR EXCHANGE ON THIS ITEM SINCE IT REQUIRES SPECIAL HANDLING 
JARID2 inhibits leukemia cell proliferation by regulating CCND1 expression.

JARID2 inhibits leukemia cell proliferation by regulating CCND1 expression.

Int J Hematol. 2015 May 5;

Authors: Su CL, Deng TR, Shang Z, Xiao Y

Abstract
It has recently been shown that JARID2 contributes to the malignant character of solid tumors, such as epithelial-mesenchymal transition in lung and colon cancer cell lines, but its role in leukemia progression is unexplored. In this study, we explored the effect and underlying molecular mechanism of JARID2 on leukemia cell proliferation. Real-time PCR and Western assay were carried out to detect JARID2 and CCND1 expression. Cell number and cell cycle change were detected using hemocytometer and flow cytometry, and a ChIP assay was utilized to investigate JARID2 and H3K27me3 enrichment on the CCND1 promoter. JARID2 is down-regulated in B-chronic lymphocytic leukemia (B-CLL) and acute monocytic leukemia (AMOL), and knockdown of JARID2 promotes leukemia cell proliferation via acceleration of the G1/S transition. Conversely, ectopic expression of JARID2 inhibits these malignant phenotypes. Mechanistic studies show that JARID2 negatively regulates CCND1 expression by increasing H3K27 trimethylation on the CCND1 promoter. Our findings indicate that JARID2 is a negative regulator of leukemia cell proliferation, and functions as potential tumor suppressor in leukemia.

PMID: 25939703 [PubMed - as supplied by publisher]



via pubmed: cllsllupdate1 http://ift.tt/1OZX0Q9
The cannabinoid system could be a potential target for pharmacological treatment of Kaposi's sarcoma.

PMID:  Eur J Pharmacol. 2009 Aug 15 ;616(1-3):16-21. Epub 2009 Jun 17. PMID: 19539619 Abstract Title:  The CB1/CB2 receptor agonist WIN-55,212-2 reduces viability of human Kaposi’s sarcoma cells in vitro. Abstract:  Kaposi’s sarcoma is a highly vascularized mesenchymal neoplasm arising with multiple lesions of the skin. Endogenous cannabinoids have been shown to inhibit proliferation of a wide spectrum of tumor cells. We studied the effects of cannabinoids on human Kaposi’s sarcoma cell proliferation in vitro. To do so, we first investigated the presence of the cannabinoid receptors CB(1) and CB(2) mRNAs in the human Kaposi’s sarcoma cell line KS-IMM by RT-PCR and, subsequently, the effects of the mixed CB(1)/CB(2) agonist WIN-55,212-2 (WIN) on cell proliferation in vitro. WIN showed antimitogenic effects on Kaposi’s sarcoma cells. Western blot analysis of Kaposi’s sarcoma lysates suggested that WIN treatment induced activation of both caspase-3 and -6, as well as increased phosphorylation of the stress kinase p38 and JNK, along with transient phosphorylation of ERK(½). To better characterize the involvement of each single CB receptor in cannabinoid-induced cell death, we incubated Kaposi’s sarcoma cells with different selective cannabinoid receptor agonists, respectively ACEA (CB(1)) and JWH-133 (CB(2)). None of the agonists was able to induce KS-IMM cell apoptosis. Moreover, we co-incubated Kaposi’s sarcoma cells with WIN-55,212-2 and either the CB(1) receptor antagonist AM251, the CB(2) receptor antagonist AM630, or a combination of both substances. The CB(2) receptor antagonist AM630 was able to significantly increase survival of Kaposi’s sarcoma cells treated with WIN. In view of the antiproliferative effects of cannabinoids on KS-IMM cells, one could envision the cannabinoid system as a potential target for pharmacological treatment of Kaposi’s sarcoma. http://j.mp/1IdYnFm

This study highlights the potential therapeutic usefulness of curcumin as an adjunct in patients with chemoresistant advanced CRC.

PMID:  Carcinogenesis. 2015 Mar ;36(3):355-67. Epub 2015 Feb 4. PMID: 25653233 Abstract Title:  Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer. Abstract:  Resistance to cytotoxic chemotherapy is a major cause of mortality in colorectal cancer (CRC) patients. Chemoresistance has been linked primarily to a subset of cancer cells undergoing epithelial-mesenchymal transition (EMT). Curcumin, a botanical with antitumorigenic properties, has been shown to enhance sensitivity of cancer cells to chemotherapeutic drugs, but the molecular mechanisms underlying this phenomenon remain unclear. Effects of curcumin and 5-fluorouracil (5FU) individually, and in combination, were examined in parental and 5FU resistant (5FUR) cell lines. We performed a series of growth proliferation and apoptosis assays in 2D and 3D cell cultures. Furthermore, we identified and analyzed the expression pattern of a subset of putative EMT-suppressive microRNAs (miRNAs) and their downstream target genes regulated by curcumin. Chemosensitizing effects of curcumin were validated in a xenograft mouse model. Combined treatment with curcumin and 5FU enhanced cellular apoptosis and inhibited proliferation in both parental and 5FUR cells, whereas 5FU alone was ineffective in 5FUR cells. A group of EMT-suppressive miRNAs were upregulated by curcumin treatment in 5FUR cells. Curcumin suppressed EMT in 5FUR cells by downregulating BMI1, SUZ12 and EZH2 transcripts, key mediators of cancer stemness-related polycomb repressive complex subunits. Using a xenograft and mathematical models, we further demonstrated that curcumin sensitized 5FU to suppress tumor growth. We provide novel mechanistic evidence for curcumin-mediated sensitization to 5FU-related chemoresistance through suppression of EMT in 5FUR cells via upregulation of EMT-suppressive miRNAs. This study highlights the potential therapeutic usefulness of curcumin as an adjunct in patients with chemoresistant advanced CRC. http://j.mp/1I1YxzE

IJMS, Vol. 16, Pages 9693-9718: #microRNA Expression Profile of Neural Progenitor-Like Cells Derived from Rat Bone Marrow Mesenchymal Stem Cells under the Influence of IGF-1, bFGF and EGF

Insulin-like growth factor 1 (IGF-1) enhances cellular proliferation and reduces apoptosis during the early differentiation of bone marrow derived mesenchymal stem cells (BMSCs) into neural progenitor-like cells (NPCs) in the presence of epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF). BMSCs were differentiated in three groups of growth factors: (A) EGF + bFGF, (B) EGF + bFGF + IGF-1, and © without growth factor. To unravel the molecular mechanisms of the NPCs derivation, microarray analysis using GeneChip® #miRNA arrays was performed. The profiles were compared among the groups. Annotated #microRNA fingerprints (GSE60060) delineated 46 micro#RNAs temporally up-regulated or down-regulated compared to group C. The expressions of selected micro#RNAs were validated by real-time PCR. Among the 46 micro#RNAs, 30 were consistently expressed for minimum of two consecutive time intervals. In Group B, only miR-496 was up-regulated and 12 micro#RNAs, including the let-7 family, miR-1224, miR-125a-3p, miR-214, miR-22, miR-320, miR-708, and miR-93, were down-regulated. Bioinformatics analysis reveals that some of these micro#RNAs (miR-22, miR-214, miR-125a-3p, miR-320 and let-7 family) are associated with reduction of apoptosis. Here, we summarize the roles of key micro#RNAs associated with IGF-1 in the differentiation of BMSCs into NPCs. These findings may provide clues to further our understanding of the mechanisms and roles of micro#RNAs as key regulators of BMSC-derived NPC maintenance. http://bit.ly/1OCMsWX #MDPI